Patricia A. Bradford, Director at Phio Pharmaceuticals Corp. (PHIO), bought 12,000 shares at $1.03 ($12K) on 2026-09-15, disclosed to the SEC on 2026-09-16.
Director Patricia A. Bradford purchased 12,000 shares for $12,360 at $1.03, marking the largest insider purchase in the company's history, which may signal confidence in the stock's valuation following recent patent milestones. The trade occurred while the stock is trading near its 52-week low, suggesting a potential contrarian entry point.
PHIO is down 2.88% over the last 5 days and 6.05% over the last 30 days, trading at $1.01, which is 17.89% below its 52-week high of $1.23.
1) Upcoming Q3 earnings on October 29, 2026; 2) The company received three notices of allowance and one patent grant decision on July 15, 2026, strengthening its INTASYL® platform IP; 3) This is the largest insider purchase ever recorded for the company.
The stock is trading at a forward P/E of -1.64, indicating significant losses are expected, and short interest remains elevated at 1.92% of the float.
Something here stands out, but not much.
| Filing → |